Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
sleeping child baby

3 indications auguring well for the future of pediatric PET/MRI

In pediatric care settings, hybrid PET/MR imaging combines “exquisite soft-tissue information obtained by MR imaging with functional information provided by PET.”

Thumbnail

FDA clears spinal-tap test that could challenge PET in Alzheimer’s diagnostics

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

The American Society of Nuclear Cardiology (ASNC) is asking Congress to repeal the appropriate use software provision mandate, which physicians say is an obstacle to efficient care.

VIDEO: Imaging societies ask Congress to repeal appropriate use decision support mandate

Randall Thompson, MD, immediate past president of the American Society of Nuclear Cardiology (ASNC), explains the current ASNC lobbying efforts.

Thumbnail

CMS coverage decision for Alzheimer's drug, related PET scans sparks concern in imaging community

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

coronavirus COVID-19 vaccine vaccination

FDG PET/CT radiomics distinguishes between vaccine-related or metastatic breast cancer lymphadenopathy

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested. 

healthcare value value-based care money dollar

New imaging technique could provide cheaper alternative to costly PET scanners

Resource-challenged providers in rural areas and elsewhere may not always have access to this technology, given the hefty price tag, experts wrote Monday. 

brain money alzheimer dementia

Imaging industry advocate slams feds’ failure to address PET coverage gap in recent ruling

The Society for Nuclear Medicine & Molecular Imaging expressed "strong opposition" following CMS' decision, arguing there is no evidence to support limiting pay for such scans. 

prostate cancer PSA

Combination therapy that includes new radionuclide proves effective for metastatic prostate cancer

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

Displaying 233 - 240 of 329
Design by Adaptive Theme